Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Change in Intangibles (2019)

Historic Change in Intangibles for Ligand Pharmaceuticals (LGNYZ) over the last 2 years, with Q1 2019 value amounting to $812.8 million.

  • Ligand Pharmaceuticals' Change in Intangibles changed N/A to $812.8 million in Q1 2019 from the same period last year, while for Dec 2019 it was $812.8 million, marking a year-over-year change of. This contributed to the annual value of $812.8 million for FY2019, which is N/A changed from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Change in Intangibles of $812.8 million as of Q1 2019.
  • Ligand Pharmaceuticals' Change in Intangibles' 5-year high stood at $812.8 million during Q1 2019, with a 5-year trough of $812.8 million in Q1 2019.